• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

p53 失活后有序且确定的癌症基因组进化。

Ordered and deterministic cancer genome evolution after p53 loss.

机构信息

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Department of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.

出版信息

Nature. 2022 Aug;608(7924):795-802. doi: 10.1038/s41586-022-05082-5. Epub 2022 Aug 17.

DOI:10.1038/s41586-022-05082-5
PMID:35978189
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9402436/
Abstract

Although p53 inactivation promotes genomic instability and presents a route to malignancy for more than half of all human cancers, the patterns through which heterogenous TP53 (encoding human p53) mutant genomes emerge and influence tumorigenesis remain poorly understood. Here, in a mouse model of pancreatic ductal adenocarcinoma that reports sporadic p53 loss of heterozygosity before cancer onset, we find that malignant properties enabled by p53 inactivation are acquired through a predictable pattern of genome evolution. Single-cell sequencing and in situ genotyping of cells from the point of p53 inactivation through progression to frank cancer reveal that this deterministic behaviour involves four sequential phases-Trp53 (encoding mouse p53) loss of heterozygosity, accumulation of deletions, genome doubling, and the emergence of gains and amplifications-each associated with specific histological stages across the premalignant and malignant spectrum. Despite rampant heterogeneity, the deletion events that follow p53 inactivation target functionally relevant pathways that can shape genomic evolution and remain fixed as homogenous events in diverse malignant populations. Thus, loss of p53-the 'guardian of the genome'-is not merely a gateway to genetic chaos but, rather, can enable deterministic patterns of genome evolution that may point to new strategies for the treatment of TP53-mutant tumours.

摘要

尽管 p53 失活会促进基因组不稳定,并为超过一半的人类癌症提供恶性转化途径,但异质性 TP53(编码人类 p53)突变基因组出现并影响肿瘤发生的模式仍知之甚少。在这里,在一种报告在癌症发生前散发性 p53 杂合性丢失的胰腺导管腺癌小鼠模型中,我们发现 p53 失活所赋予的恶性特性是通过可预测的基因组进化模式获得的。从 p53 失活到进展为明确癌症的细胞的单细胞测序和原位基因分型揭示了这种确定性行为涉及四个连续阶段-Trp53(编码小鼠 p53)杂合性丢失、缺失积累、基因组加倍以及增益和扩增的出现-每个阶段都与癌前和恶性谱中的特定组织学阶段相关。尽管存在广泛的异质性,但紧随 p53 失活之后的缺失事件靶向功能相关途径,这些途径可以塑造基因组进化,并在不同的恶性群体中作为同质事件固定下来。因此,p53(“基因组的守护者”)的丧失不仅是通向遗传混乱的门户,而且可以实现基因组进化的确定性模式,这可能为治疗 TP53 突变肿瘤指明新的策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/7c25b3171848/41586_2022_5082_Fig17_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/53eaeae06f01/41586_2022_5082_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/1f8421d55e53/41586_2022_5082_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/744be84730a6/41586_2022_5082_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/80a0ba006eef/41586_2022_5082_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/fc31acda9e78/41586_2022_5082_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/796cdcebe244/41586_2022_5082_Fig6_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/842733e4ff5e/41586_2022_5082_Fig7_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/8629a2aa891e/41586_2022_5082_Fig8_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/4978be186916/41586_2022_5082_Fig9_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/5d21084b7615/41586_2022_5082_Fig10_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/a8c2c0b75893/41586_2022_5082_Fig11_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/2c787fe3d524/41586_2022_5082_Fig12_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/863719decedf/41586_2022_5082_Fig13_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/b28b8a649d32/41586_2022_5082_Fig14_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/08459b04d395/41586_2022_5082_Fig15_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/77f5943f5ba6/41586_2022_5082_Fig16_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/7c25b3171848/41586_2022_5082_Fig17_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/53eaeae06f01/41586_2022_5082_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/1f8421d55e53/41586_2022_5082_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/744be84730a6/41586_2022_5082_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/80a0ba006eef/41586_2022_5082_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/fc31acda9e78/41586_2022_5082_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/796cdcebe244/41586_2022_5082_Fig6_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/842733e4ff5e/41586_2022_5082_Fig7_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/8629a2aa891e/41586_2022_5082_Fig8_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/4978be186916/41586_2022_5082_Fig9_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/5d21084b7615/41586_2022_5082_Fig10_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/a8c2c0b75893/41586_2022_5082_Fig11_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/2c787fe3d524/41586_2022_5082_Fig12_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/863719decedf/41586_2022_5082_Fig13_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/b28b8a649d32/41586_2022_5082_Fig14_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/08459b04d395/41586_2022_5082_Fig15_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/77f5943f5ba6/41586_2022_5082_Fig16_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/188d/9402436/7c25b3171848/41586_2022_5082_Fig17_ESM.jpg

相似文献

1
Ordered and deterministic cancer genome evolution after p53 loss.p53 失活后有序且确定的癌症基因组进化。
Nature. 2022 Aug;608(7924):795-802. doi: 10.1038/s41586-022-05082-5. Epub 2022 Aug 17.
2
Loss of p53 and genetic evolution in pancreatic cancer: Ordered chaos after the guardian is gone.胰腺癌中 p53 的缺失与遗传进化:守护者离去后的有序混乱。
Cancer Cell. 2022 Nov 14;40(11):1276-1278. doi: 10.1016/j.ccell.2022.10.020.
3
Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse.p16(Ink4a)和p19(Arf)-p53通路均限制小鼠胰腺腺癌的进展。
Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5947-52. doi: 10.1073/pnas.0601273103. Epub 2006 Apr 3.
4
Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma.突变型 p53R270H 驱动胰腺导管腺癌代谢改变和侵袭增强。
JCI Insight. 2018 Jan 25;3(2). doi: 10.1172/jci.insight.97422.
5
Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers.Kras 驱动型癌症中杂合性缺失后 p53 的克隆动态。
Nat Commun. 2016 Sep 2;7:12685. doi: 10.1038/ncomms12685.
6
Of autophagy and in vivo pancreatic carcinogenesis: the p53 status matters!自噬与体内胰腺癌发生:p53状态至关重要!
Clin Res Hepatol Gastroenterol. 2014 Sep;38(4):423-5. doi: 10.1016/j.clinre.2014.04.009. Epub 2014 Jun 14.
7
Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer.Brca2 失活与 Trp53(R172H) 协同作用诱导小鼠侵袭性胰腺导管腺癌:家族性胰腺癌的小鼠模型。
Cancer Biol Ther. 2011 Jun 1;11(11):959-68. doi: 10.4161/cbt.11.11.15534.
8
SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.SETDB1抑制p53介导的细胞凋亡,是小鼠胰腺导管腺癌形成所必需的。
Gastroenterology. 2020 Aug;159(2):682-696.e13. doi: 10.1053/j.gastro.2020.04.047. Epub 2020 Apr 28.
9
Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis.胰腺肿瘤:导管癌中涉及的分子途径参与壶腹癌的发生,但不参与外分泌非导管性或内分泌肿瘤的发生。
Br J Cancer. 2001 Jan;84(2):253-62. doi: 10.1054/bjoc.2000.1567.
10
Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer.胚系 BRCA2 杂合性促进家族性胰腺癌小鼠模型中 Kras(G12D)驱动的癌变。
Cancer Cell. 2010 Nov 16;18(5):499-509. doi: 10.1016/j.ccr.2010.10.015. Epub 2010 Nov 4.

引用本文的文献

1
Dissecting cross-lineage tumourigenesis under p53 inactivation through single-cell multi-omics and spatial transcriptomics.通过单细胞多组学和空间转录组学剖析p53失活状态下的跨谱系肿瘤发生
Clin Transl Med. 2025 Sep;15(9):e70461. doi: 10.1002/ctm2.70461.
2
Variation at the R181 residue of p53 confers loss of p53 DNA binding cooperativity with the retention of mitochondrial-associated apoptosis.p53的R181残基处的变异导致p53 DNA结合协同性丧失,同时保留与线粒体相关的细胞凋亡。
bioRxiv. 2025 Aug 13:2025.08.12.669925. doi: 10.1101/2025.08.12.669925.
3
Risk factors for multiple myeloma and its precursor diseases.

本文引用的文献

1
MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution.MEDICC2:用于癌症进化的全基因组倍增意识拷贝数系统发育。
Genome Biol. 2022 Nov 14;23(1):241. doi: 10.1186/s13059-022-02794-9.
2
Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma.水平调节胰腺导管腺癌中的转移异质性。
Cancer Discov. 2022 Feb;12(2):542-561. doi: 10.1158/2159-8290.CD-20-1826. Epub 2021 Sep 22.
3
Breast tumours maintain a reservoir of subclonal diversity during expansion.乳腺肿瘤在扩增过程中维持亚克隆多样性的储备。
多发性骨髓瘤及其前驱疾病的危险因素。
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2025 Apr 28;50(4):560-572. doi: 10.11817/j.issn.1672-7347.2025.240594.
4
Functions of Intrinsically Disordered Regions.内在无序区域的功能。
Biology (Basel). 2025 Jul 4;14(7):810. doi: 10.3390/biology14070810.
5
Mathematical bridge between epidemiological and molecular data on cancer and beyond.癌症及其他领域流行病学数据与分子数据之间的数学桥梁。
PLoS One. 2025 Jul 28;20(7):e0328401. doi: 10.1371/journal.pone.0328401. eCollection 2025.
6
Ongoing genome doubling shapes evolvability and immunity in ovarian cancer.持续的基因组加倍塑造了卵巢癌的进化能力和免疫特性。
Nature. 2025 Jul 16. doi: 10.1038/s41586-025-09240-3.
7
Development and extensive sequencing of a broadly-consented Genome in a Bottle matched tumor-normal pair.对广泛认可的“瓶中基因组”匹配的肿瘤-正常样本对进行开发及深度测序。
Sci Data. 2025 Jul 16;12(1):1195. doi: 10.1038/s41597-025-05438-2.
8
Local Adaptive Mapping of Karyotype Fitness Landscapes.核型适应度景观的局部自适应映射
bioRxiv. 2025 Jun 21:2023.07.14.549079. doi: 10.1101/2023.07.14.549079.
9
Induction of cancer stem cells from mouse fibroblasts.从小鼠成纤维细胞诱导生成癌症干细胞。
Sci Rep. 2025 Jul 15;15(1):25489. doi: 10.1038/s41598-025-09686-5.
10
Oncogenic and tumor-suppressive forces converge on a progenitor-orchestrated niche to shape early tumorigenesis.致癌力量和肿瘤抑制力量汇聚于祖细胞精心构建的生态位,以塑造早期肿瘤发生。
bioRxiv. 2025 Jun 12:2025.06.10.656791. doi: 10.1101/2025.06.10.656791.
Nature. 2021 Apr;592(7853):302-308. doi: 10.1038/s41586-021-03357-x. Epub 2021 Mar 24.
4
A gene-environment-induced epigenetic program initiates tumorigenesis.基因-环境诱导的表观遗传程序引发肿瘤发生。
Nature. 2021 Feb;590(7847):642-648. doi: 10.1038/s41586-020-03147-x. Epub 2021 Feb 3.
5
Pervasive chromosomal instability and karyotype order in tumour evolution.肿瘤进化中的普遍染色体不稳定性和核型顺序。
Nature. 2020 Nov;587(7832):126-132. doi: 10.1038/s41586-020-2698-6. Epub 2020 Sep 2.
6
Integrated Computational Pipeline for Single-Cell Genomic Profiling.单细胞基因组分析的集成计算管道。
JCO Clin Cancer Inform. 2020 May;4:464-471. doi: 10.1200/CCI.19.00171.
7
Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue.代表性测序:实体瘤组织的无偏采样。
Cell Rep. 2020 May 5;31(5):107550. doi: 10.1016/j.celrep.2020.107550.
8
The evolutionary history of 2,658 cancers.2658 种癌症的进化史。
Nature. 2020 Feb;578(7793):122-128. doi: 10.1038/s41586-019-1907-7. Epub 2020 Feb 6.
9
Pan-cancer analysis of whole genomes.泛癌症全基因组分析。
Nature. 2020 Feb;578(7793):82-93. doi: 10.1038/s41586-020-1969-6. Epub 2020 Feb 5.
10
Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution.胰腺癌的转录表型是由肿瘤进化过程中的基因组事件驱动的。
Nat Genet. 2020 Feb;52(2):231-240. doi: 10.1038/s41588-019-0566-9. Epub 2020 Jan 13.